Does the media favor ELAN or ADPT?

In the previous week, Elanco Animal Health had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 9 mentions for Elanco Animal Health and 5 mentions for Adaptive Biotechnologies. Elanco Animal Health's average media sentiment score of 1.31 beat Adaptive Biotechnologies' score of 0.51 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or ADPT?

In the previous week, Axsome Therapeutics had 9 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 14 mentions for Axsome Therapeutics and 5 mentions for Adaptive Biotechnologies. Axsome Therapeutics' average media sentiment score of 0.61 beat Adaptive Biotechnologies' score of 0.51 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SMMT or ADPT?

In the previous week, Summit Therapeutics and Summit Therapeutics both had 5 articles in the media. Adaptive Biotechnologies' average media sentiment score of 0.51 beat Summit Therapeutics' score of 0.42 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADPT or ABVX?

In the previous week, Adaptive Biotechnologies and Adaptive Biotechnologies both had 5 articles in the media. Abivax's average media sentiment score of 1.41 beat Adaptive Biotechnologies' score of 0.51 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ADPT or RDY?

Adaptive Biotechnologies presently has a consensus price target of $20.83, indicating a potential downside of 5.77%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to ADPT or RDY?

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 4 mentions for Dr. Reddy's Laboratories. Adaptive Biotechnologies' average media sentiment score of 0.51 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Adaptive Biotechnologies (ADPT) Competitors

$22.11 -0.81 (-3.54%)

As of 02:14 PM Eastern

Compare

ADPT vs. ELAN, AXSM, SMMT, ABVX, and RDY

Should you buy Adaptive Biotechnologies stock or one of its competitors? MarketBeat compares Adaptive Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adaptive Biotechnologies include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), Abivax (ABVX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Adaptive Biotechnologies compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Elanco Animal Health currently has a consensus price target of $28.55, indicating a potential upside of 11.92%. Adaptive Biotechnologies has a consensus price target of $20.83, indicating a potential downside of 5.77%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Elanco Animal Health is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Elanco Animal Health had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 9 mentions for Elanco Animal Health and 5 mentions for Adaptive Biotechnologies. Elanco Animal Health's average media sentiment score of 1.31 beat Adaptive Biotechnologies' score of 0.51 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Adaptive Biotechnologies has lower revenue, but higher earnings than Elanco Animal Health. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.70	-$232M	-$0.50	N/A
Adaptive Biotechnologies	$276.98M	12.77	-$59.50M	-$0.33	N/A

Elanco Animal Health has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

Elanco Animal Health has a net margin of -4.95% compared to Adaptive Biotechnologies' net margin of -16.82%. Elanco Animal Health's return on equity of 7.42% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Summary

Elanco Animal Health beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Adaptive Biotechnologies has lower revenue, but higher earnings than Axsome Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.27	-$183.17M	-$3.73	N/A
Adaptive Biotechnologies	$276.98M	12.77	-$59.50M	-$0.33	N/A

Axsome Therapeutics presently has a consensus target price of $259.05, indicating a potential upside of 14.25%. Adaptive Biotechnologies has a consensus target price of $20.83, indicating a potential downside of 5.77%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Adaptive Biotechnologies has a net margin of -16.82% compared to Axsome Therapeutics' net margin of -26.59%. Adaptive Biotechnologies' return on equity of -40.06% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

In the previous week, Axsome Therapeutics had 9 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 14 mentions for Axsome Therapeutics and 5 mentions for Adaptive Biotechnologies. Axsome Therapeutics' average media sentiment score of 0.61 beat Adaptive Biotechnologies' score of 0.51 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market.

Summary

Axsome Therapeutics beats Adaptive Biotechnologies on 10 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Adaptive Biotechnologies has higher revenue and earnings than Summit Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Adaptive Biotechnologies	$276.98M	12.77	-$59.50M	-$0.33	N/A

Summit Therapeutics has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summit Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

In the previous week, Summit Therapeutics and Summit Therapeutics both had 5 articles in the media. Adaptive Biotechnologies' average media sentiment score of 0.51 beat Summit Therapeutics' score of 0.42 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics presently has a consensus price target of $26.97, suggesting a potential upside of 94.34%. Adaptive Biotechnologies has a consensus price target of $20.83, suggesting a potential downside of 5.77%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Adaptive Biotechnologies beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Abivax?

Adaptive Biotechnologies (NASDAQ:ADPT) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Adaptive Biotechnologies has higher revenue and earnings than Abivax. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	12.77	-$59.50M	-$0.33	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Adaptive Biotechnologies currently has a consensus price target of $20.83, suggesting a potential downside of 5.77%. Abivax has a consensus price target of $148.54, suggesting a potential upside of 10.32%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Abivax has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Abivax	N/A	-99.02%	-70.26%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies and Adaptive Biotechnologies both had 5 articles in the media. Abivax's average media sentiment score of 1.41 beat Adaptive Biotechnologies' score of 0.51 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market. Comparatively, Abivax has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Summary

Adaptive Biotechnologies beats Abivax on 8 of the 14 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Dr. Reddy's Laboratories?

Adaptive Biotechnologies (NASDAQ:ADPT) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Adaptive Biotechnologies has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	12.77	-$59.50M	-$0.33	N/A
Dr. Reddy's Laboratories	$3.58B	2.93	$456M	$0.58	21.66

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 4 mentions for Dr. Reddy's Laboratories. Adaptive Biotechnologies' average media sentiment score of 0.51 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Adaptive Biotechnologies' net margin of -16.82%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Adaptive Biotechnologies presently has a consensus price target of $20.83, indicating a potential downside of 5.77%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Adaptive Biotechnologies beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.54B	$3.65B	$6.81B	$12.34B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-66.94	20.87	27.16	24.06
Price / Sales	12.77	302.93	573.91	113.10
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	15.04	7.99	10.68	6.17
Net Income	-$59.50M	$23.81M	$3.59B	$331.63M
7 Day Performance	5.18%	-1.94%	-1.50%	-1.48%
1 Month Performance	26.02%	2.01%	1.17%	-1.20%
1 Year Performance	112.79%	43.81%	24.50%	17.62%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	1.5317 of 5 stars	$22.11 -3.5%	$20.83 -5.8%	+120.6%	$3.54B	$276.98M	N/A	790	Analyst Forecast
ELAN Elanco Animal Health	3.8519 of 5 stars	$25.13 +1.2%	$28.55 +13.6%	+74.8%	$12.40B	$4.72B	N/A	9,400	Positive News
AXSM Axsome Therapeutics	3.7592 of 5 stars	$228.28 -2.4%	$259.05 +13.5%	+105.9%	$12.03B	$638.50M	N/A	380	Analyst Forecast
SMMT Summit Therapeutics	3.2598 of 5 stars	$15.30 +0.3%	$26.97 +76.3%	-47.3%	$11.84B	N/A	N/A	110	News Coverage Upcoming Earnings Analyst Downgrade
ABVX Abivax	2.4393 of 5 stars	$135.98 -2.8%	$148.54 +9.2%	+1,273.4%	$11.16B	N/A	N/A	61	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Adaptive Biotechnologies compare to Elanco Animal Health?

Summary

How does Adaptive Biotechnologies compare to Axsome Therapeutics?

Summary

How does Adaptive Biotechnologies compare to Summit Therapeutics?

Summary

How does Adaptive Biotechnologies compare to Abivax?

Summary

How does Adaptive Biotechnologies compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Adaptive Biotechnologies compare to Elanco Animal Health?

Do analysts rate ELAN or ADPT?

Does the media favor ELAN or ADPT?

Do insiders & institutionals believe in ELAN or ADPT?

Which has higher earnings and valuation, ELAN or ADPT?

Which has more volatility & risk, ELAN or ADPT?

Is ELAN or ADPT more profitable?

Summary

How does Adaptive Biotechnologies compare to Axsome Therapeutics?

Do insiders and institutionals believe in AXSM or ADPT?

Which has preferable valuation & earnings, AXSM or ADPT?

Do analysts prefer AXSM or ADPT?

Is AXSM or ADPT more profitable?

Does the media prefer AXSM or ADPT?

Which has more risk & volatility, AXSM or ADPT?

Summary

How does Adaptive Biotechnologies compare to Summit Therapeutics?

Which has better earnings and valuation, SMMT or ADPT?

Which has more risk & volatility, SMMT or ADPT?

Do insiders and institutionals have more ownership in SMMT or ADPT?

Is SMMT or ADPT more profitable?

Does the media favor SMMT or ADPT?

Do analysts prefer SMMT or ADPT?

Summary

How does Adaptive Biotechnologies compare to Abivax?

Which has preferable valuation & earnings, ADPT or ABVX?

Do analysts prefer ADPT or ABVX?

Is ADPT or ABVX more profitable?

Do insiders & institutionals hold more shares of ADPT or ABVX?

Does the media prefer ADPT or ABVX?

Which has more volatility and risk, ADPT or ABVX?

Summary

How does Adaptive Biotechnologies compare to Dr. Reddy's Laboratories?

Which has more risk & volatility, ADPT or RDY?

Which has better earnings and valuation, ADPT or RDY?

Does the media refer more to ADPT or RDY?

Is ADPT or RDY more profitable?

Do insiders and institutionals believe in ADPT or RDY?

Do analysts prefer ADPT or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools